• Explore /
  • Poster
  • / CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).

CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).

Abstract Poster

Authors

null

Eric Xueyu Chen

Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada

Eric Xueyu Chen , Derek J. Jonker , Hagen F. Kennecke , Scott R. Berry , Felix Couture , Chaudhary E. Ahmad , John R. Goffin , Petr Kavan , Mohammed Harb , Bruce Colwell , Setareh Samimi , Benoit Samson , Tahir Abbas , Nathalie Aucoin , Francine Aubin , Sheryl L. Koski , Alice Chia-chi Wei , Nadine M Magoski , Dongsheng Tu , Christopher J. O'Callaghan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT02870920

Citation

J Clin Oncol 37, 2019 (suppl 4; abstr 481)

DOI

10.1200/JCO.2019.37.4_suppl.481

Abstract #

481

Poster Bd #

C2

Abstract Disclosures

Similar Posters

First Author: Eric Xueyu Chen

First Author: Eric Xueyu Chen

First Author: Jonathan M. Loree

First Author: Viktor Grünwald